Even CHKP much slower growth is trading at 10 time sales....and FTNT is at 8 times sales. GIMO is STILL TOO CHEAP a security play !!
if security stocks are trading at these valuations, GIMO needs to catch up, now that they have become a security play. Look at earnings and growth this qtr and next.
market has found its new momentum stock like CYBR.
worry they will run out of cash at this rate.
which his right ?
are you dreaming..miss is 3milion. they reported 142.8m, and the est was 145.9 million. missed earnings by 0.02. look up yahoo earnings dude.
plus revenue miss was 3 mil..that is 2% miss below estimates. Hardly a big miss.
Most of it was due to currency issues. CEO will talk tomorrow.
est was 0.08, not .10....so they missed by 0.02. Stock is down 15% this year already, even after the big beat last qtr. Plus stock trading at 1.5 sales.
I would say most of this miss priced in.
if CEO gives bullish outlook stock will do well tomorrow.
are you kidding me ?
here is the proof -
As of August 9, 2013, a total of 77 BT requests have been received and 25 approved. 27 have been denied and 25 are still pending (source: FDA, Orphan Druganaut Blog).
look it up...for BTD given so far, 25 have failed, 25 or so under review, and 30 or so approved. Don't have exact numbers, but this is what I remember seeing. Seach it up.
So there is no such thing at 100% approval for BTD.
so the hospitalization reduction is not really the number they published. Mycar works yes, it showed efficiency after 2 years, even 3 years...but big question is...how much better is it going to be against placebo in phase 2b. Just working is not good enough..it has to show the 45% number. And with 125 patients each, they cannot get healthier patients in the high dose group.
what is MB ? Do you know why the disconnect in valuation ??
both are in phase 2....WHY ??
that's because I sold, and am looking to get in at lower prices..so trying to scare people here a bit.
This could be why hospitalizations were much less for dose arm than placebo. With 250 patients now with Ph 2, the 45% hospalization target is not so low anymore ??
Placebo High Dose Arm
High Cholesterol 92% 44%
Hypertension 71% 44%
Arrhythmia 71% 55%
CAD 71% 22%
MI 57% 22%
Angina 35% 11%
PVD 28% 0%
Ischemic HD 50% 22%
Pfizer, Bristol Myers also investors in ATHX..look at it now.
usually bio stocks run up before data....going down is not good. Plus they did a secondary 3 weeks ago...so raising money just before data is also not good sign.
in a spike in stock price.
IT IS NOT FIRST TIME GENE THERAPY !! QURE already has the same gene therapy vector AAV approved for use in Europe !! Look it up.